The need for clarification of percent risk reduction data in clinical cardiovascular trial reports
- 1 March 1989
- journal article
- editorial
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 13 (3), 764-766
- https://doi.org/10.1016/0735-1097(89)90623-2
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987
- Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacinJournal of the American College of Cardiology, 1986
- Diltiazem and Reinfarction in Patients with Non-Q-Wave Myocardial InfarctionNew England Journal of Medicine, 1986
- Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart FailureNew England Journal of Medicine, 1986
- Aspirin, Sulfinpyrazone, or Both in Unstable AnginaNew England Journal of Medicine, 1985
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJama-Journal Of The American Medical Association, 1984
- Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable AnginaNew England Journal of Medicine, 1983
- A Randomized Trial of Propranolol in Patients With Acute Myocardial InfarctionJama-Journal Of The American Medical Association, 1982
- Timolol-Induced Reduction in Mortality and Reinfarction in Patients Surviving Acute Myocardial InfarctionNew England Journal of Medicine, 1981
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958